Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

A Novel Hydrogen Sulfide Prodrug, SG 1002, Promotes Hydrogen Sulfide and Nitric Oxide Bioavailability in Heart Failure Patients

Open access
Polhemus, David J., Li, Zhen, Pattillo, Christopher B., Gojon, Gabriel, Gojon, Gabriel, Giordano, Tony, Krum, Henry·2015·Cardiovascular Therapeutics

Abstract

Summary: Recent studies demonstrate robust molecular cross talk and signaling between hydrogen sulfide (H 2 S) and nitric oxide (NO). Heart failure (HF) patients are deficient in both H 2 S and NO, two molecules that are critical for cardiovascular homeostasis. A phase I clinical trial of a novel H 2 S prodrug (SG 1002) was designed to assess safety and changes in H 2 S and NO bioavailability in healthy and HF subjects. Healthy subjects (n = 7) and heart failure patients (n = 8) received oral SG 1002 treatment in escalating dosages of 200, 400, and 800 mg twice daily for 7 days for each dose. Safety and tolerability were assessed by physical examination, vital signs, and ECG analysis. Plasma samples were collected during a 24‐h period each week for H 2 S and NO analysis. BNP and glutathione levels were analyzed as markers of cardiac health and redox status. Administration of SG 1002 resulted in increased H 2 S levels in healthy subjects. We also observed increased H 2 S levels in HF subjects following 400 mg SG 1002. Nitrite, a metabolite of NO, was increased in both healthy and HF patients receiving 400 mg and 800 mg SG 1002. HF subjects treated with SG 1002 displayed stable drug levels over the course of the trial. SG 1002 was safe and well tolerated at all doses in both healthy and HF subjects. These data suggest that SG 1002 increases blood H 2 S levels and circulating NO bioavailability. The finding that SG 1002 attenuates increases in BNP in HF patients suggests that this novel agent warrants further study in a larger clinical study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/1755-5922.12128

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 169

Metadata

Authors
Polhemus, D. J., Li, Z., Pattillo, C. B., Gojon, G., Gojon, G., Giordano, T., & Krum, H.
Venue
Cardiovascular Therapeutics
Publisher
Wiley
Published
2015-07-07
Volume
33
Issue
4
Pages
216-226
ISSN
  • 1755-5914 (ISSN-L)
  • 1755-5922
OpenAlex
W2009296914
Cited by
169
References
9
FWCI
5.17
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Novel Hydrogen Sulfide Prodrug, SG 1002, Promotes Hydrogen Sulfide and Nitric Oxide Bioavailability in Heart Failure Patients. https://app.cochat.ai/papers/10.1111/1755-5922.12128
The paper
Polhemus, D. J., Li, Z., Pattillo, C. B., Gojon, G., Gojon, G., Giordano, T., & Krum, H. (2015). A Novel Hydrogen Sulfide Prodrug, SG 1002, Promotes Hydrogen Sulfide and Nitric Oxide Bioavailability in Heart Failure Patients. Cardiovascular Therapeutics. https://doi.org/10.1111/1755-5922.12128

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.